



Ulf Wiinberg

Independent Director

Member of the Board since 2016

Member of the Audit Committee from 2016 to 2021

Date of birth: 1958

Nationality: Danish/Swedish

Gender: Male

End of term: 2024

Introduction & Professional experience

Ulf Wiinberg serves as CEO of X-Vax Therapy Inc, since April 2017. X-Vax Therapy Inc is a privately held biotech company operating out of Jupiter Florida. The main mission of the company is to develop a vaccine and/or a therapeutic against Herpes Simplex.

Ulf also serves on the following listed company boards, in addition to UCB: Hansa Biopharma - Lund Sweden - as Chairman, Alfa Laval AB - Lund Sweden - as a Director, and Agenus Inc, an immune oncology company - Lexington Massachusetts - as a Director.

Ulf has a long career in the Pharma industry at senior levels. Ulf was CEO at Lundbeck from June 2008 to December 2014. Ulf was also part of the Wyeth Management committee from January 2002 to June 2008. During this time Ulf was worldwide President of Wyeth Consumer Health care from 2002 to 2005, and President for Europe / Middle East / Africa until June 2008. Wyeth was acquired by Pfizer in 2009.

Ulf has also served on the most important industry boards in different capacities.

Ulf brings to our board experience of biotechnology, pharmaceutical and healthcare industries globally.

Education

Nicolai High School – 1997

Main external appointments

Member of the Board of Alfa Laval AB*

Member of the Board of Agenus Inc* and Chair of the Audit and Finance Committee

Chairman of the Board of Hansa Medical*

CEO of X-Vax Therapeutics Inc.

** Listed companies*